Press releasePRNewswire
Regulus Therapeutics
RGLS · NASDAQ
Price unavailable right now.
No price history for this range.
Latest news
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders
- Press releaseBusiness Wire
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS
- NewsAvi Kapoor
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, SWTX on Behalf of Shareholders
- Press releasePRNewswire
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher
- NewsVandana Singh
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
- NewsAvi Kapoor
S&P 500 Falls 2%; Caterpillar Reports Downbeat Q1 Results
- Press releaseBusiness Wire
RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseBusiness Wire
Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders
- Press releasePRNewswire
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
- Press releasePRNewswire
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releasePRNewswire
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Press releasePRNewswire
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates
- Press releasePRNewswire
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference
- Press releasePRNewswire
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- Press releasePRNewswire
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)
- Press releasePRNewswire
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences
- Press releasePRNewswire
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
- Press releasePRNewswire
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Press releasePRNewswire
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
- Press releasePRNewswire
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
- Press releasePRNewswire
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.